Name | proglumide |
Synonyms | ProM proglumide PROGLUMIDE LABOTEST-BB LT00772215 N-Benzoyl-N′,N′-dipropyl-DL-isoglutamine N~2~-benzoyl-N,N-dipropyl-alpha-glutamine N(2)-benzoyl-N,N-dipropyl-alpha-glutamine 4-benzamido-N,N-dipropyl-DL-glutaramic acid 4-BenzaMido-5-(dipropylaMino)-5-oxopentanoic acid 4-(BenzoylaMino)-5-(dipropylaMino)-5-oxo-pentanoic Acid |
CAS | 6620-60-6 |
EINECS | 229-567-4 |
InChI | InChI=1/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22) |
Molecular Formula | C18H26N2O4 |
Molar Mass | 334.41 |
Density | 1.1944 (rough estimate) |
Melting Point | 148-150°C |
Boling Point | 471.21°C (rough estimate) |
Flash Point | 310.5°C |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 9.33E-15mmHg at 25°C |
Appearance | Solid |
Color | Crystals |
pKa | 4.51±0.10(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Room Temperature |
Refractive Index | 1.5700 (estimate) |
Physical and Chemical Properties | Colorless crystals or crystalline powders. Melting point 142-145 ℃, soluble in ethanol, methanol, chloroform, insoluble in acetone, water, benzene, almost insoluble in carbon tetrachloride. Odorless and bitter. |
Use | Gastrin receptor antagonist for gastric and duodenal ulcer disease |
Toxicity | LD50 in mice (mg/kg): 2211-2649 i.v.; 7350-8861 orally (Rovati) |
This product is (±)-4-benzamido-n, N-dipropylpentanamic acid. Calculated as dried product, the content of C18H26N204 shall not be less than 99.0%.
The melting point of this product (General 0612) is 148.5~152°C.
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.99 ml | 14.952 ml | 29.903 ml |
5 mM | 0.598 ml | 2.99 ml | 5.981 ml |
10 mM | 0.299 ml | 1.495 ml | 2.99 ml |
5 mM | 0.06 ml | 0.299 ml | 0.598 ml |
The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 67).
take 2.0g of this product, add 1 ml of nitric acid, dilute to 50ml with water, shake, filter, take 25ml of filtrate, check according to law (General rule 0801), not more concentrated (0.005%) than the control solution made from of standard sodium chloride solution.
take this product, add mobile phase to dissolve and dilute to make a solution containing about 1 mg per 1ml as a test solution; Take 1ml for precision measurement and put it in a 200ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. According to the determination of HPLC (General 0512), silica gel bonded with eighteen alkyl silane was used as filler; Methanol-acetonitrile -2% ammonium acetate solution (30:10:60) was used as mobile phase; the detection wavelength was 240mn. The number of theoretical plates shall not be less than 3000 based on the calculation of proglumide peak. 20 u1 of each of the control solution and the test solution were injected into the liquid chromatograph respectively, and the chromatogram was recorded to 4 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (0.5%).
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
take this product about 0.3g, precision weighing, add neutral ethanol (phenolphthalein indicator solution neutral) 30ml dissolved, add phenolphthalein indicator solution 2 drops, with sodium hydroxide titration solution (0.lmol/L) titration. Each 1 ml of sodium hydroxide titration solution (0.1 mol/L) corresponds to 33.44mg of C18H26N204.
acid inhibitor.
sealed storage.
This product containing proglumide should be labeled amount of 95.0% ~ 105.0%.
This product is white tablet.
Same as proglumide.
0.2g
light shielding, sealed storage.
This product contains Proglumide (C18H26N204) should be 95.0% ~ 105.0% of the label.
Same as proglumide.
0.2g
sealed storage.
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
Introduction | proglumide is the first discovered gastrin antagonist, and both progluric acid and benzotript are derivatives. proglumide, also a racemic compound named (±)-5-dipropylamino-4-benzoylamino-5-oxo-pentanoic acid, recorded in the Chinese Pharmacopoeia 2000 edition, Part Two, page 96, for the gastrin receptor antagonist, chemical structure and gastrin (G-17) and cholecystokinin (CCK) the terminal chemical structures of the two kinds of intestinal kinins are similar. Its functional group, Amide group, competes specifically with gastrin for gastrin receptors on parietal cells, thus it can significantly inhibit the secretion of gastric acid and pepsin caused by gastrin, but has no obvious effect on the secretion of gastric acid caused by histamine and vagus nerve stimulation. |
indications | for gastric and duodenal ulcer, gastritis (such as Chronic superficial gastritis) and duodenal inflammation. |
pharmacological action | This product is cholecystokinin receptor and gastrin receptor antagonist, its molecular structure and gastrin (G-17) and cholecystokinin (CCK) two kinds of intestinal kinin terminal molecular structure is similar, so the functional group amide group can be specific and G-17 competing with the Wall cell G-17 receptor, it can obviously inhibit the secretion of gastric acid and pepsin caused by G-17, increase the content of amino hexose in gastric mucosa, promote the synthesis of glycoprotein, protect gastric mucosa, so as to improve the symptoms of peptic ulcer and promote the healing of ulcer. The inhibitory effect of this product on gastric acid secretion caused by histamine and vagus nerve stimulation is not obvious, and the rebound phenomenon of gastric acid secretion does not occur in the treatment of peptic ulcer and gastritis, gastric acid secretion can still be at a normal level for half a year after termination of treatment. Because this product inhibits the role of gastric acid secretion than H2 receptor antagonists weak, clinical is no longer used alone for the treatment of ulcer disease, but recently its choleretic effect more attention. |
drug interaction | 1. In combination with other anti-ulcer drugs (such as H2 receptor antagonists), it can enhance the effect of inhibiting gastric acid secretion and accelerate the healing of ulcer. 2. Combined with morphine, can enhance the analgesic effect of morphine and prolong the duration of its action. 3. This product can antagonize the effect of haloperidol to make the movement disorder worse, so the treatment of Huntington's Chorea can not be combined. |
preparation | 1) preparation of N-benzoic acid glutamic acid a 1000 mL three-necked flask was charged with 50 g sodium gallate chlorate, 400 of water and appropriate amount of NaOH. Dissolve with stirring, adjust pH 7-8, add 37.2 mL of benzoyl chloride and 40% NaOH Dropwise below 2 ℃, control reaction temperature below 5 ℃, pH 8. Reaction at 5 deg C for 1 h, with 30% HCI adjusted to pH 1.5, cooling, crystallization, filtration, drying, N-benzoyl glutamic acid crude 71.8g,mp 134~140 deg C. 2) preparation of proglumide 60g(10.24 mot) of crude N-benzoylglutamic acid and 30g(0.22 mol) of acetic anhydride were taken. Add 75 mL of toluene to 500 mL three-mouth bottle, react at 85 ℃ for 30min, steam under normal pressure until no liquid drops out (toluene recovery and application), add 300 mL of ice water. Dipropylamine, 80mL, to be dissolved. React at 0 °c for 1 h, add acetic acid to adjust pH 4.5, stir, crystallize, dilute. The filter cake was added directly without drying. Distilled water, sodium carbonate and activated carbon were decolorized at 80 ℃ for 30min, filtered while hot, the filtrate was adjusted to pH 4.5, cooled, crystallized, filtered and dried to obtain 39 g of fine product, mp l48 ~ 151 ℃, the overall yield was 53.79%. |
Use | This product is a gastrin receptor antagonist, which has the function of protecting gastric mucosa and promoting ulcer healing. Suitable for gastric and duodenal ulcer, gastritis, Stress ulcer, etc., the effective rate of 81-96%, the application of this product does not occur acid rebound increase, and the recurrence rate is low. gastrin receptor antagonist for gastric and duodenal ulcer disease |
production method | N-benzoyl glutamic acid was obtained from glutamic acid and benzoyl chloride, then acetic anhydride is reacted to obtain N-benzoyl glutamic anhydride, and then aminated with dipropylamine to obtain proglumide. Based on glutamic acid, the overall yield was 26-30%. |
category | toxic substances |
toxicity grade | poisoning |
Acute toxicity | intraperitoneal-rat LD50: 1420 mg/kg; Oral-mouse LD50: 8070 mg/kg |
flammability hazard characteristics | flammability; Toxic NOx smoke from combustion |
storage and transportation characteristics | ventilation and low temperature drying |
fire extinguishing agent | dry powder, foam, sand, carbon dioxide, water mist |